SG11202108089SA - Administration of pd-1 inhibitors for treating skin cancer - Google Patents
Administration of pd-1 inhibitors for treating skin cancerInfo
- Publication number
- SG11202108089SA SG11202108089SA SG11202108089SA SG11202108089SA SG11202108089SA SG 11202108089S A SG11202108089S A SG 11202108089SA SG 11202108089S A SG11202108089S A SG 11202108089SA SG 11202108089S A SG11202108089S A SG 11202108089SA SG 11202108089S A SG11202108089S A SG 11202108089SA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- administration
- skin cancer
- treating skin
- treating
- Prior art date
Links
- 239000012270 PD-1 inhibitor Substances 0.000 title 1
- 239000012668 PD-1-inhibitor Substances 0.000 title 1
- 208000000453 Skin Neoplasms Diseases 0.000 title 1
- 229940121655 pd-1 inhibitor Drugs 0.000 title 1
- 201000000849 skin cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962811827P | 2019-02-28 | 2019-02-28 | |
PCT/US2020/020018 WO2020176699A1 (en) | 2019-02-28 | 2020-02-27 | Administration of pd-1 inhibitors for treating skin cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202108089SA true SG11202108089SA (en) | 2021-08-30 |
Family
ID=70057261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202108089SA SG11202108089SA (en) | 2019-02-28 | 2020-02-27 | Administration of pd-1 inhibitors for treating skin cancer |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220259313A1 (es) |
EP (1) | EP3930848A1 (es) |
JP (1) | JP2022521800A (es) |
KR (1) | KR20210134690A (es) |
CN (1) | CN113490529A (es) |
AU (1) | AU2020228296A1 (es) |
CA (1) | CA3137361A1 (es) |
IL (1) | IL285050A (es) |
MA (1) | MA55084A (es) |
MX (1) | MX2021010228A (es) |
SG (1) | SG11202108089SA (es) |
WO (1) | WO2020176699A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
KR20230141869A (ko) * | 2021-02-11 | 2023-10-10 | 리제너론 파마슈티칼스 인코포레이티드 | 신보조 요법으로서 pd-1 저해제의 투여에 의한 암 치료 방법 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0013581A (pt) | 1999-08-23 | 2002-07-02 | Dana Faber Cancer Inst Inc | Pd-1, um receptor para b7-4, e usos para isto |
PT2206517T (pt) | 2002-07-03 | 2023-11-07 | Tasuku Honjo | Composições de imunopotenciação contendo anticorpos anti-pd-l1 |
ATE514713T1 (de) | 2002-12-23 | 2011-07-15 | Wyeth Llc | Antikörper gegen pd-1 und ihre verwendung |
DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
CA3201163A1 (en) | 2005-07-01 | 2007-01-11 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
ES2616355T3 (es) | 2007-06-18 | 2017-06-12 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor humano de muerte programada PD-1 |
WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
PL2350129T3 (pl) | 2008-08-25 | 2015-12-31 | Amplimmune Inc | Kompozycje antagonistów PD-1 i sposoby stosowania |
KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-pd-1, pd-l1, 및 pd-l2 항체 및 그의 용도 |
HRP20240240T1 (hr) | 2008-12-09 | 2024-04-26 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
AU2012288413B2 (en) | 2011-07-24 | 2016-10-13 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
DK2785375T3 (da) | 2011-11-28 | 2020-10-12 | Merck Patent Gmbh | Anti-pd-l1-antistoffer og anvendelser deraf |
CN104736168B (zh) | 2012-05-31 | 2018-09-21 | 索伦托治疗有限公司 | 与pd-l1结合的抗原结合蛋白 |
EP3556776A1 (en) | 2012-05-31 | 2019-10-23 | F. Hoffmann-La Roche AG | Methods of treating cancer using pd-1 axis binding antagonists and vegf antagonists |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
NZ766660A (en) | 2014-08-05 | 2024-02-23 | Cb Therapeutics Inc | Anti-pd-l1 antibodies |
MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
WO2017106656A1 (en) * | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
SI3394103T1 (sl) | 2015-12-22 | 2023-10-30 | Regeneron Pharmaceuticals, Inc. | Kombinacija protiteles proti-PD-1 in bispecifičnih protiteles proti-CD20/proti-CD3 za zdravljenje raka |
RU2745195C2 (ru) | 2016-04-07 | 2021-03-22 | Кемосентрикс, Инк. | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами |
TWI755395B (zh) | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
AU2018225102A1 (en) | 2017-02-21 | 2019-09-05 | Regeneron Pharmaceuticals, Inc. | Anti-PD-1 antibodies for treatment of lung cancer |
US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
US11542312B2 (en) * | 2017-06-19 | 2023-01-03 | Medicenna Therapeutics, Inc. | IL-2 superagonists in combination with anti-PD-1 antibodies |
-
2020
- 2020-02-27 JP JP2021550167A patent/JP2022521800A/ja active Pending
- 2020-02-27 AU AU2020228296A patent/AU2020228296A1/en active Pending
- 2020-02-27 CA CA3137361A patent/CA3137361A1/en active Pending
- 2020-02-27 MX MX2021010228A patent/MX2021010228A/es unknown
- 2020-02-27 CN CN202080017060.8A patent/CN113490529A/zh active Pending
- 2020-02-27 SG SG11202108089SA patent/SG11202108089SA/en unknown
- 2020-02-27 US US17/433,003 patent/US20220259313A1/en active Pending
- 2020-02-27 EP EP20715554.0A patent/EP3930848A1/en active Pending
- 2020-02-27 MA MA055084A patent/MA55084A/fr unknown
- 2020-02-27 WO PCT/US2020/020018 patent/WO2020176699A1/en unknown
- 2020-02-27 KR KR1020217030808A patent/KR20210134690A/ko unknown
-
2021
- 2021-07-22 IL IL285050A patent/IL285050A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020176699A1 (en) | 2020-09-03 |
EP3930848A1 (en) | 2022-01-05 |
IL285050A (en) | 2021-09-30 |
KR20210134690A (ko) | 2021-11-10 |
CN113490529A (zh) | 2021-10-08 |
MX2021010228A (es) | 2021-10-26 |
AU2020228296A1 (en) | 2021-10-14 |
MA55084A (fr) | 2022-01-05 |
JP2022521800A (ja) | 2022-04-12 |
CA3137361A1 (en) | 2020-09-03 |
US20220259313A1 (en) | 2022-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL262561B (en) | Methods for treating skin cancer by administering a pd-1 inhibitor | |
IL284324A (en) | Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer | |
IL284326A (en) | Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer | |
EP3464643A4 (en) | USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER | |
EP3890749A4 (en) | CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS CANCER TREATMENT AGENT | |
IL268676A (en) | Inhibition of SMARCA2 for cancer therapy | |
EP3782618A4 (en) | METHOD OF PREVENTING OR TREATING SIDE EFFECTS OF CANCER THERAPY | |
HK1244436A1 (zh) | 治療癌症的hsp90抑制劑和pd-1抑制劑的組合療法 | |
IL285050A (en) | Administering PD-1 inhibitors for the treatment of skin cancer | |
IL291170A (en) | Cancer treatment lacks hr | |
IL274198A (en) | Use of Nox inhibitors to treat cancer | |
EP3630080A4 (en) | USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER | |
IL291424A (en) | Use of dkk-1 inhibitors to treat cancer | |
FI3880186T3 (fi) | PD-1-inhibiittoreiden intralesionaalinen antaminen ihosyövän hoitamiseksi | |
EP3758678A4 (en) | CANCER TREATMENT METHODS INCLUDING CHK1 INHIBITORS | |
EP3947460A4 (en) | MULTISPECIFIC AGENTS FOR TREATMENT OF CANCER | |
IL270948A (en) | Combination of regorfenib and PD-1/PD-L1(2) for cancer treatment | |
EP3856352A4 (en) | Methods of treatment of cancer comprising cdc7 inhibitors | |
IL287538A (en) | Preparations and methods for the treatment of cancer | |
IL288003A (en) | Cancer treatment methods using chk1 inhibitors | |
IL289201A (en) | Compounds for the treatment of cancer | |
EP3615052A4 (en) | USE OF HCN INHIBITORS FOR CANCER TREATMENT | |
EP3989949A4 (en) | INHIBITION OF PRC1 FOR THE TREATMENT OF CANCER |